BJ-3105

has anti-inflammatory activity; inhibits IFN-gamma and IL-17 production; reduces Th1 and Th17 cell populations; structure in first source

Also Known As:

2,4,5-trimethyl-6-(3-phenylpropoxy)pyridin-3-ol

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - BJ-3105: 2

Experts

1.	Jeong, Byeong-Seon: 2 articles (04/2020 - 01/2017)
2.	Chaudhary, Prakash: 1 article (04/2020)
3.	Dahal, Sadan: 1 article (04/2020)
4.	Guragain, Diwakar: 1 article (04/2020)
5.	Gurung, Pallavi: 1 article (04/2020)
6.	Karmacharya, Ujjwala: 1 article (04/2020)
7.	Kim, Jung-Ae: 1 article (04/2020)
8.	Chang, Jae-Hoon: 1 article (01/2017)
9.	Dahal, Ishmit: 1 article (01/2017)
10.	Kang, Youra: 1 article (01/2017)

Related Diseases

1.	Disease Progression 01/01/2017 - "BJ-3105, a 6-Alkoxypyridin-3-ol Analog, Impairs T Cell Differentiation and Prevents Experimental Autoimmune Encephalomyelitis Disease Progression."
2.	Neoplasms (Cancer) 04/29/2020 - "In mice, oral administration with BJ-3105 ameliorated dextran sulfate sodium (DSS)-induced colitis and azoxymethane/DSS-induced colitis-associated tumor formation (CAT) much more potently than that with tofacitinib. "
3.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/01/2017 - "BJ-3105 ameliorated the experimental autoimmune encephalomyelitis (EAE) model by reducing Th1 and Th17 generation. " 01/01/2017 - "BJ-3105, a 6-Alkoxypyridin-3-ol Analog, Impairs T Cell Differentiation and Prevents Experimental Autoimmune Encephalomyelitis Disease Progression."
4.	Colitis 04/29/2020 - "Potent Inhibitory Effect of BJ-3105, a 6-Alkoxypyridin-3-ol Derivative, on Murine Colitis Is Mediated by Activating AMPK and Inhibiting NOX." 04/29/2020 - "Taken together, our findings suggest BJ-3105, which exerted a much better anti-colitis effect than tofacitinib through AMPK activation and NOX inhibition, is a promising candidate for the treatment of IBD." 04/29/2020 - "Moreover, BJ-3105 suppressed the more severe form of colitis and CAT formation in mice with AMPK knocked-out in macrophages (AMPKαfl/fl-Lyz2-Cre mice) with much greater efficacy than tofacitinib. " 04/29/2020 - "In mice, oral administration with BJ-3105 ameliorated dextran sulfate sodium (DSS)-induced colitis and azoxymethane/DSS-induced colitis-associated tumor formation (CAT) much more potently than that with tofacitinib. "

Related Drugs and Biologics

1.	Dextran Sulfate
2.	Azoxymethane
3.	tofacitinib

Related Therapies and Procedures

1.	Oral Administration